Form D · Pharmaceuticals

Volastra Therapeutics, Inc.

New York, NY · CIK 0001968822

Offering snapshot reported Sep 23, 2025 · SEC filing

Reported sold
$30.1M
Offering amount: $30.1M
Investors reported
11
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 8, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Sep 23, 2025Initial$30,099,998No comparison11SEC filing
May 30, 2024Initial$15,000,000No comparison2SEC filing
Mar 13, 2023Initial$60,174,997No comparison13SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-558375

Source: Form D, filed Sep 23, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Samuel Bakhoum Director
Arjun Balar Director
Luc Dochez Director
Scott Drutman Executive
Jill Goldstein Director
Rez Halze Director
Charles Hugh Jones Director, Executive
Eileen Mc Guire Director
Ellie Mc Guire Director
Robert Mittendorff Director
David Nicholson Director
Sandra Peterson Director
Amy Schulman Director
Rachel Zolot Schwartz Executive
David Southwell Director, Executive
Michael Su Executive
Diane Tager Executive
Stefan Vitorovic Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
1361 Amsterdam Avenue Suite 520
New York, NY, 10027
Phone: 646-344-1248